<?xml version='1.0' encoding='utf-8'?>
<document id="31012522"><sentence text="Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus."><entity charOffset="67-78" id="DDI-PubMed.31012522.s1.e0" text="cannabidiol" /><entity charOffset="83-93" id="DDI-PubMed.31012522.s1.e1" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.31012522.s1.e0" e2="DDI-PubMed.31012522.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31012522.s1.e0" e2="DDI-PubMed.31012522.s1.e1" /></sentence><sentence text="Cannabidiol (CBD), a major purified nonpsychoactive component of cannabis with anticonvulsant properties, was approved by the U"><entity charOffset="0-11" id="DDI-PubMed.31012522.s2.e0" text="Cannabidiol" /><entity charOffset="13-16" id="DDI-PubMed.31012522.s2.e1" text="CBD" /><pair ddi="false" e1="DDI-PubMed.31012522.s2.e0" e2="DDI-PubMed.31012522.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31012522.s2.e0" e2="DDI-PubMed.31012522.s2.e1" /></sentence><sentence text="S" /><sentence text=" Food and Drug Administration (FDA) in June 2018 as an adjuvant treatment for refractory epilepsy (Epidiolex; GW Pharmaceuticals)" /><sentence text=" CBD is metabolized by cytochrome P450 (CYP)3A4 and CYP2C19 with a growing body of evidence suggesting it is also a potent inhibitor of these pathways"><entity charOffset="1-4" id="DDI-PubMed.31012522.s5.e0" text="CBD" /></sentence><sentence text=" We report for the first time a significant drug-drug interaction between the purified CBD product and tacrolimus"><entity charOffset="103-113" id="DDI-PubMed.31012522.s6.e0" text="tacrolimus" /><entity charOffset="87-96" id="DDI-PubMed.31012522.s6.e1" text="CBD" /><pair ddi="false" e1="DDI-PubMed.31012522.s6.e1" e2="DDI-PubMed.31012522.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31012522.s6.e1" e2="DDI-PubMed.31012522.s6.e0" /></sentence><sentence text=" A participant in a CBD clinical trial for epilepsy who was also receiving tacrolimus showed an approximately 3-fold increase in dose-normalized tacrolimus concentrations while receiving 2000-2900Â mg/day of CBD"><entity charOffset="20-23" id="DDI-PubMed.31012522.s7.e0" text="CBD" /><entity charOffset="75-85" id="DDI-PubMed.31012522.s7.e1" text="tacrolimus" /><entity charOffset="145-155" id="DDI-PubMed.31012522.s7.e2" text="tacrolimus" /><entity charOffset="207-210" id="DDI-PubMed.31012522.s7.e3" text="CBD" /><pair ddi="false" e1="DDI-PubMed.31012522.s7.e0" e2="DDI-PubMed.31012522.s7.e0" /><pair ddi="false" e1="DDI-PubMed.31012522.s7.e0" e2="DDI-PubMed.31012522.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31012522.s7.e0" e2="DDI-PubMed.31012522.s7.e2" /><pair ddi="false" e1="DDI-PubMed.31012522.s7.e0" e2="DDI-PubMed.31012522.s7.e3" /><pair ddi="false" e1="DDI-PubMed.31012522.s7.e1" e2="DDI-PubMed.31012522.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31012522.s7.e1" e2="DDI-PubMed.31012522.s7.e2" /><pair ddi="false" e1="DDI-PubMed.31012522.s7.e1" e2="DDI-PubMed.31012522.s7.e3" /><pair ddi="false" e1="DDI-PubMed.31012522.s7.e2" e2="DDI-PubMed.31012522.s7.e2" /><pair ddi="false" e1="DDI-PubMed.31012522.s7.e2" e2="DDI-PubMed.31012522.s7.e3" /></sentence><sentence text=" Our report delineates an important concern for the transplant community with the increasing legalization of cannabis and advent of an FDA-approved CBD product"><entity charOffset="148-151" id="DDI-PubMed.31012522.s8.e0" text="CBD" /></sentence><sentence text=" Larger studies are needed to better understand the impact of this drug-drug interaction in solid organ transplant recipients" /><sentence text="" /></document>